Orion Oyj (FRA:OFK)

Market Cap	11.48B +24.5%
Revenue (ttm)	2.06B +22.7%
Net Income	587.10M +55.3%
EPS	4.17 +55.1%
Shares Out	n/a
PE Ratio	19.55
Forward PE	18.60
Dividend	1.80 (2.22%)
Ex-Dividend Date	Oct 19, 2026

Volume	n/a
Open	81.30
Previous Close	81.35
Day's Range	81.25 - 81.30
52-Week Range	56.95 - 82.10
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychoti...

• Industry: Pharmaceutical Preparations
• Founded: 1917
• Employees: 4,000
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: OFK

Financial Performance

In 2025, Orion Oyj's revenue was 1.89 billion, an increase of 22.50% compared to the previous year's 1.54 billion. Earnings were 500.30 million, an increase of 51.65%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 20, 2026

Data Sources Report a data error